PURE Bioscience Reports Year End Results

SAN DIEGO, Calif., OCT. 29, 2007 – PURE Bioscience (OTCBB: PURE), creators of patented silver dihydrogen citrate (SDC), the active ingredient in a revolutionary new hard surface disinfectant that kills Staph/MRSA as well as other human pathogens, today reported financial results for the year ended July 31, 2007.  Revenues of $336,400 increased 68% compared with revenues of $200,432 in the prior year.  The Company reported a loss from operations before taxes of $(4,840,800), or $(0.19) per share, compared with a loss of $(3,712,600), or $(0.19) per share, in the prior year.

Michael L. Krall, President and CEO of PURE Bioscience, commented on the progress made during the year, “In fiscal 2007 we continued to lay the groundwork needed to more fully develop opportunities for our SDC platform technology: 1) production and private label distribution development for ready-to-use EPA-registered disinfectant products, 2) establishment of channels for distribution of varying strengths of SDC concentrate as an active ingredient, additive or preservative for inclusion in third party products, including household and personal care products, and 3) continued pursuit of development programs for SDC as an active pharmaceutical ingredient in a variety of pharmaceutical products.  To meet anticipated demand, we completed a facility expansion to increase ourcapacity to produce concentrate from $7 million to $250 million per year and obtained cGMP certification of the manufacturing facility and process for the production of pharmaceutical-grade SDC concentrate as an Active Pharmaceutical Ingredient (API).

“The immediate elimination and continued prevention of Staph/MRSA at the Tulsa County Jail after 14 months of using our disinfectant validates the efficacy and practicality of implementing the SDC-based disinfectant into emergency and routine cleaning procedures.  In our research and development program, we had identified and prepared for the rapid emergence of Staph infections as a common health hazard, and we are confident that our disinfectant provides a solution to this problem.

“In addition to growing the private label program for our SDC-based disinfectant, in this past year we signed distributors in Brazil and Asia, expanded our patent portfolio and, with a pharmaceutical development partner, filed an investigational new drug application with the US Food and Drug Administration for an SDC-based hand sanitizer for which clinical trials are now underway.  In addition, we successfully completed our R&D and third party laboratory testing on our new SDC-based product, Cruise Control™.  Cruise Control dilutable concentrate will be marketed to the cruise ship industry and is the first disinfecting product to offer 24-hour residual protection against Norovirus.”

Krall also commented on the future outlook, “We view 2008 as our breakout year for a number of reasons.  Intense media coverage has focused the public’s attention on Staph, and based on recent feedback from our private label distributors, we anticipate notable growth in private label distribution of SDC-based disinfectants.  In addition, we expect to sign several pending distribution agreements in the coming weeks, and we will continue pursuing partnerships with industry leading companies in new markets for SDC.

“We are also optimistic about the tremendous market opportunity for Cruise Control™; furthermore, we look forward to our distributors in Brazil and Asia placing their first orders for concentrate after receipt of local regulatory approvals early in calendar 2008.  We expect the current IND for hand sanitizer to progress toward approval, and we look forward to establishing additional development relationships to further explore SDC as an active pharmaceutical ingredient for other applications, including wound and burn care, dental, veterinary and systemic antibacterial, antiviral and antifungal products as well as for medical device applications.

Krall concluded, “Lastly, with the equity financing completed this month we are one step closer to listing on a national exchange – a move I believe will bring increased exposure and liquidity to our stock in 2008.”

About PURE Bioscience

PURE Bioscience (PURE) develops and markets technology-based bioscience products that provide solutions to numerous global health challenges, including Staph (MRSA). PURE's proprietary high efficacy/low toxicity bioscience technologies, including its silver dihydrogen citrate-based antimicrobials, represent innovative advances in diverse markets and lead today's global trend toward industry and consumer use of "green" products while providing competitive advantages in efficacy and safety.  Patented silver dihydrogen citrate (SDC) is an electrolytically generated source of stabilized ionic silver.  SDC is colorless, odorless, tasteless, non-toxic, non-caustic and formulates well with other compounds.  As a platform technology, SDC is distinguished from competitors in the marketplace because of its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it.  SDC also offers 24-hour residual protection against standard indicator bacteria.  PURE Bioscience, headquartered in El Cajon, California (San Diego metropolitan area), was incorporated in 1992.  Additional information on PURE Bioscience is available at www.purebio.com.

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project,” "expect" or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, acceptance of the Company's current and future products and services in the marketplace, the ability of the Company to develop effective new products and receive regulatory approvals of such products, competitive factors, dependence upon third-party vendors, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.